Table 5.

Clinicopathological features of PTC-FV cases with respect to BRAF and NRAS mutations.

Variables	BRAF mutation n (%) n = 6		No BRAF mutation n (%) n = 31		P-value	NRAS mutation n (%) n = 6		No NRAS mutation n (%) n = 18		P-value
Age (years)					0.952					0.974
Mean ± SD	40.8 ± 17.4		45.5 ± 12.9			41.5 ± 11.7		41.4 ± 12.9
Gender					0.653					0.280
Female	4	(66.7)	23	(74.2)		6	(100.0)	13	(72.2)
Male	2	(33.3)	8	(25.8)		0	(0.0)	5	(27.8)
Stage					1.000					1.000
I	4	(66.7)	17	(54.8)		4	(66.7)	12	(66.7)
II	1	(16.7)	8	(25.8)		1	(16.7)	3	(16.7)
III	1	(16.7)	5	(16.1)		1	(16.7)	2	(11.1)
IV	0	(0.0)	0	(0.0)		0	(0.0)	0	(0.0)
Not available	0	(0.0)	1	(3.2)		0	(0.0)	1	(5.6)
Focality					0.383					1.000
Unifocal	4	(66.7)	13	(41.9)		2	(33.3)	8	(44.4)
Multifocal	2	(33.3)	18	(58.1)		4	(66.7)	10	(55.6)
Not available	0	(0.0)	0	(0.0)		0	(0.0)	0	(0.0)
Size					0.293					0.724
≤3	6	(100.0)	20	(64.5)		4	(66.7)	13	(72.2)
>3	0	(0.0)	10	(32.3)		2	(33.3)	4	(22.2)
Not available	0	(0.0)	1	(3.2)		0	(0.0)	1	(5.6)
Extrathyroidal extension					0.571					0.546
Present	0	(0.0)	7	(22.6)		0	(0.0)	3	(16.7)
Absent	6	(100.0)	24	(77.4)		6	(100.0)	15	(83.3)
Not available	0	(0.0)	0	(0.0)		0	(0.0)	0	(0.0)
Lymphovascular invasion					0.097					0.251
Present	0	(0.0)	7	(22.6)		2	(33.3)	1	(5.6)
Absent	5	(83.3)	24	(77.4)		4	(66.7)	16	(88.9)
Not available	1	(16.7)	0	(0.0)		0	(0.0)	1	(5.6)
Lymphnodes status					0.307					1.000
Positive	1	(16.7)	1	(3.2)		0	(0.0)	2	(11.1)
Negative	1	(16.7)	11	(35.5)		2	(33.3)	7	(38.9)
Not available	4	(66.7)	19	(61.3)		4	(66.7)	9	(50.0)

*Significant difference.